Edwar, Sarah Qanita
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Herpes Zoster Reactivation Following COVID-19 mRNA Vaccination in an Elderly Patient: A Case Report Sarah, Ratu Siti Khadijah; Hapsari, Yari Castiliani; Yusharyahya, Shannaz Nadia; Miranda, Eliza; Edwar, Sarah Qanita
Journal of General - Procedural Dermatology and Venereology Indonesia Vol. 9, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Latent varicella-zoster virus (VZV) in nerve ganglia may reactivate into herpes zoster infection. The coronavirus disease (COVID-19) vaccine is suspected of triggering VZV reactivation, although the exact cause is unclear. This case report aims to raise awareness of the potential complications induced by the COVID-19 mRNA vaccine, particularly in elderly patients. Case Illustration: A 62-year-old woman complained of itchy and painful unilateral dermatomal herpetiform blisters six days after mRNA COVID-19 vaccination. The vesicle first appeared on the left breast, spreading to the back. The patient has a history of hypertension. After the administration of 800 mg of acyclovir five times a day for seven days, the vesicles dried up, and no new vesicles emerged. Discussion: The incidence of herpes zoster has been widely reported to occur within 5-7 days after the COVID-19 vaccination, mostly due to the mRNA vaccine. The dysregulated cell-mediated immune system may trigger VZV reactivation. The vaccines have been shown to induce a cellular response with increased CD8+ T-cells and T-helper type 1 CD4+ T cells. The VZV-specific CD8+ cells cannot control VZV after the massive shift of naïve CD8+ T-cells in the setting of COVID-19 vaccination. Hypertension is also allegedly the main comorbid factor for herpes zoster reactivation after COVID-19 vaccination. Conclusion: Increased awareness and early recognition of potential COVID-19 vaccine-related complications, especially in elderly individuals with comorbidities, are important for timely management and prevention of further issues.
Prognosis of early-onset alopecia areata: An evidence-based case report Edwar, Sarah Qanita; Legiawati, Lili; Anggraini, Stefani Reditya; Sarah, Ratu Siti Khadijah
Journal of General - Procedural Dermatology and Venereology Indonesia Vol. 10, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Alopecia areata (AA) is an autoimmune, non-scarring hair loss disorder commonly affecting children and often characterized by a chronic or relapsing course. Early-onset AA has traditionally been associated with a poorer prognosis, although current evidence remains inconclusive. This evidence-based case report aims to evaluate the prognostic significance of early-onset AA by synthesizing available cohort data. Methods: A structured literature search was conducted in PubMed, EMBASE, Scopus, ProQuest, and Cochrane databases using a population, intervention, comparison, and outcome framework. Keywords included “alopecia areata”, “child”, “pediatrics”, “early-onset”, “recurrence”, and “prognosis”. Results: Five retrospective cohort studies (n = 760) were included. Some studies reported higher recurrence rates in early-onset AA; one reported a 52% recurrence rate (p = 0.025). Greater baseline scalp involvement (> 50%) was associated with a higher risk of disease progression over time (OR = 1.85–2.29). However, no consistent, statistically significant differences in long-term outcomes were observed between early- and late-onset groups. Notably, children younger than 4 years showed better short-term treatment responses in certain cohorts. Discussion: Current evidence indicates that early-onset AA does not uniformly predict a poorer prognosis. Clinical outcomes are heterogeneous and appear to be more strongly influenced by baseline severity, extent of scalp involvement, and treatment response. Conclusion: Early-onset AA is not an independent predictor of poor long-term outcomes. Prognosis is variable and multifactorial, underscoring the need for individualized assessment and further age-stratified studies.